Mumps Attenuated Live Vaccine Effectiveness, Zhongshan, China, 2011-2012

Man Wang, Hm. Luo, T. Wang
Date published
Dec, 2012
Last updated
29 Jan 2020


Background: Mumps-containing vaccine (MuV) was licensed in the 1990s, and a single dose has been administered routinely to children aged 18-24 months since 2008 in China. However, an increased number of mumps cases during 2009-2012 in China required evaluation of the effectiveness of single dose MuV. In 2011, the number of reported mumps case in Zhongshan (located at the Pearl River Delta region in south China) reported the highest number cases since 1997, with incidence rate 62.9 per 100 000 population.

Methods: A 1:1 matched case-control study was conducted. The reported clinical mumps cases during May 2011 to April 2012 in Zhongshan, born 2003 to 2009, were selected. A control was chosen for each case through the vaccination information system, matched by age group, gender and living place. The system was also used to collect mumps vaccination status for each case and control. VE was calculated as one minus the adjusted matched odds ratio x 100%.

Results: 435 cases and 435 controls were included for data analysis. Among 435 cases, 209 (48.0%) had not been vaccinated, 183(42.1%) had received 1 dose, and 43 (9.9%) received 2 doses. Among 435 controls, 144(33.1%) had not been vaccinated, 241 (55.4%) had received 1 dose, and 50 (11.5%) received 2 doses. Overall the VE of the MuV against clinical mumps in children was 54% (95%CI: 37% - 67%). The estimated VE for one dose was 53% (95%CI: 34% - 66%), and 64% (95%CI: 1% - 87%) for two doses.

Conclusions: A single dose of MuV is not effective enough to interrupt community transmission of mumps. Adjusting mumps vaccine strategy is recommended in China.